TAL1 (T-cell acute lymphoblastic leukemia 1), also known as stem cell leukemia (SCL), plays important roles in differentiation of hematopoietic and endothelial cells and is deregulated in a high percentage of T-cell acute lymphoblastic leukemia (T-ALL). In this report we show that the intracellular concentration of TAL1 is regulated by transforming growth factor β (TGF-β) which triggers its polyubiquitylation and degradation by the proteasome. This effect is mediated by AKT1 which phosphorylates TAL1 at threonine 90.
Introduction
TAL1 is normally expressed in early hematopoiesis and is essential for generation of the erythroid and myeloid lineage 1 . In T-cell lineage TAL1 expression is normally repressed but is deregulated in a high percentage of T-ALL as a consequence of either chromosomal rearrangement placing the tal1 gene under sil promoter control 2,3 or epigenetic activation 4 .
Like most tissue-specific bHLH factors, TAL1 binds to E-box motifs as an heterodimer with E-proteins like E47 and it can nucleate various activatory or inhibitory protein complexes [5] [6] [7] [8] [9] .
RNA interference experiments have established that silencing of TAL1 in the Jurkat T-ALL cell line impairs their proliferation 8 . Hence a possible therapeutic approach would be to cause removal of this oncogene in T-ALL cells abnormally expressing it. In this goal we look at factors controlling stability of this protein.
In this report we show that TGF-β causes polyubiquitylation and proteasome-mediated degradation of TAL1. This effect relies on
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 4 SYBR Green RT-PCR kit (Qiagen) and the LightCycler apparatus (Roche). Sequences of sense and antisense primers were described previously 10 .
Results and Discussion

TGF-β induces degradation of TAL1
After TGF-β addition, Jurkat cells protein extracts were prepared at various times and analyzed by immunoblot using a monoclonal antibody to TAL1. At 6h, a marked reduction in the amount of intracellular TAL1 was apparent ( Figure 1A , upper panel, lane 2). It persisted at 12h and then disappeared at 24 and 48 h, likely as a consequence of receptor internalization or induction of inhibitory Smad7. Under these conditions no modification of β-actin concentration taken as a control was observed ( Figure 1A , lower panel). It was then investigated whether this decrease was related to TAL1 mRNA amount. Quantification of this mRNA did not show any significant variation ( Figure 1B ), ruling out this possibility. To test whether this TGF-β dependent decrease in TAL1 might be due to induced protein degradation, the effect of the MG132 proteasome inhibitor was examined. Both TAL1 expressed in HeLa cells and endogenous TAL1 in Jurkat cells were protected from TGF-β-induced inhibition when treated with MG132 ( Figure 1C , upper panel). It was also tested whether this effect occurs in cells taken from T-ALL patients. As shown in Figure 1D a dosedependent reduction in TAL1 intracellular concentration was also observed using cells from a patient with a sil-tal1 rearrangement. These observations support the notion that TGF-β strongly reduces the intracellular amount of TAL1 by inducing its degradation by the proteasome.
TAL1 modification by polyubiquitylation
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We further examined whether TAL1 was modified by polyubiquitylation. HeLa cells were transfected with vectors expressing FLAG-tagged TAL1 and HA-tagged ubiquitin.
TAL1 was immunoprecipitated and analyzed by immunoblot using an antibody to HA to detect ubiquitin chains associated with TAL1. This analysis indeed revealed an smear of bands above the normal position of TAL1 (supplementary Figure 1 ) which was strongly increased by treatment of the cells with the proteasome inhibitor MG132 ( Figure 1E ).
Furthermore, it was observed that TGF-β treatment is able to increase the endogenous polyubiquitylation of TAL1 (J-M Terme, data not shown). These results indicated that degradation of TAL1 induced by TGF-β correlates with its polyubiquitylation.
TGF-β-induced degradation of TAL1 involves its phosphorylation by AKT1
Polyubiquitylation of proteins is often induced by their phosphorylation. As AKT1 phosphorylates TAL1 at threonine 90 12 and as TGF-β treatment is known to activate this kinase [13] [14] [15] [16] , we tested whether it might be involved in TAL1 degradation. We observed that wortmannin completely blocks the effect of TGF-β treatment on TAL1 (Figure 2A ). degradation of TAL1, we tested whether it might also be involved in the effect of TGF-β. We thus examined whether TAL1 phosphorylation could influence its interaction with CHIP.
Interestingly, substitution of threonine 90 in aspartic acid (which mimics its phosphorylation
For personal use only. on September 24, 2017. by guest www.bloodjournal.org . These authors observed that association of TAL1 with CHIP was independent on serine 300 phosphorylation 17 . Our observations show that phosphorylation of TAL1 at threonine 90 stimulates CHIP binding. As NOTCH has recently been reported to induce the PI3K/AKT pathway 18 , it would be interesting to test a possible role of the kinase also in NOTCH-induced TAL1 degradation. Both NOTCH and TGF-β signals are important for the normal differentiation and proliferation of T lymphocytes. It will be important in future studies to examine the relationship between both pathways on the control of TAL1 degradation, especially to examine whether they exert a synergistic effect or not.
For . From this result and our observations it can be proposed that the N-terminal part of TAL1 controls its stability.
In conclusion, our results show that TGF-β regulates TAL1 stability through polyubiquitylation and proteasomal degradation. As this regulation is maintained in leukemic cells and as TAL1 is essential for their proliferation 8 , manipulating stability of this protein through TGF-β or AKT might offer interesting therapeutic approaches for the treatment of acute T-cell leukemias which abnormally express TAL1. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
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